Salim Syed

“Robert and Andrew, maybe just one from us on the dispensed versus prescribed. We're certainly getting a lot of emails just on the clarification here.”

“Just one kind of going into all the October data, obviously a lot of data that we'll be getting. Is there a bogey or measure of success that you're looking at in each of these lines that you would care to elucidate here for folks?”

“Just another one from us on the potential second line strategy here. Troy, you kind of spoke about maybe even doing some sort of doublet, I know kind of like the initial commentary was maybe going towards triplet.”

“Given that this is as an open-label study, how are you guys handling the data internally? Is this something that you plan to sort of look at as you go and you'll have knowledge to that, or is there some sort of blinded protocol even for you guys, even though it's open-label?”

“Would love to ask more than two questions here, but I'll limit myself. Coraline, Fred, maybe just one, I'll limit myself to two here. On the ATM usage, this is now the fifth quarter you guys have access to ATM in a row.”